Former Senior Vice President, Head of Research and Product Development of Alexion, will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.
List view / Grid view
Extended EU approval of Soliris to paediatric generalised myasthenia gravis (gMG) patients is based on Phase III data which demonstrated improvement in disease severity through 26 weeks.
Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
The investment in new drug substance production equipment and warehousing facilities to enhance Alexion’s biologics manufacturing in Ireland.
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
4 January 2017 | By Niamh Louise Marriott, Digital Editor
Meyenburg joins the company from Alexion Pharmaceuticals, where he most recently served as Senior Vice President of Commercial Operations.
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life...
18 February 2016 | By Victoria White
NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency...
1 September 2015 | By Nick Jackson
Alexion Pharmaceuticals, Inc. has announced that the European Commission has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency...
19 August 2015 | By Victoria White
Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine's 2015 list of the "World's Most Innovative Companies"...